Bayer (BAYN) PT Set at €111.00 by Goldman Sachs Group
Bayer (FRA:BAYN) received a €111.00 ($129.07) price target from research analysts at Goldman Sachs Group in a report released on Tuesday. The firm currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price target indicates a potential upside of 46.23% from the company’s previous close.
Several other research analysts have also recently issued reports on BAYN. UBS Group set a €130.00 ($151.16) target price on shares of Bayer and gave the stock a “buy” rating in a report on Friday, June 1st. Jefferies Financial Group set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a report on Monday, June 4th. Sanford C. Bernstein set a €120.00 ($139.53) target price on shares of Bayer and gave the stock a “buy” rating in a report on Monday, June 4th. Kepler Capital Markets set a €104.00 ($120.93) price target on shares of Bayer and gave the company a “neutral” rating in a report on Monday, June 4th. Finally, Warburg Research set a €118.00 ($137.21) price target on shares of Bayer and gave the company a “neutral” rating in a report on Monday, June 4th. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Bayer currently has a consensus rating of “Buy” and an average target price of €99.20 ($115.35).
Shares of Bayer stock opened at €75.91 ($88.27) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.